Atea Pharmaceuticals Completes Enrollment in Phase 3 HCV Trial of Bemnifosbuvir and Ruzasvir
I'm PortAI, I can summarize articles.
Atea Pharmaceuticals has completed enrollment of over 880 patients in its Phase 3 C-BEYOND trial for hepatitis C treatment, comparing bemnifosbuvir and ruzasvir to sofosbuvir and velpatasvir. The trial spans 120 sites in the US and Canada, with results expected in mid-2026. A parallel C-FORWARD trial is ongoing in 17 countries outside North America, with results anticipated by year-end 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments